Oryzon Genomics - EC taps Oryzon for healthcare initiative
The European Commission has selected Oryzon to support a new healthcare initiative furthering innovation in the region. As an associated partner of the recently announced Med4Cure initiative, Oryzon will focus on the validation of experimental epigenetic agents under a project termed VANDAM. We view this as another external endorsement of Oryzon’s robust position in epigenetics, seeking to address areas of unmet need. This collaboration opens up the potential for Oryzon along with the other two dozen selected participants to potentially access more than €6bn in funding and follows on the heels of several other notable collaborations, including the CRADA agreement with the National Cancer Institute for SCLC, the NET trial with the Fox Chase Cancer Center and the EVOLUTION trial with the Spanish Ministry of Science and Innovation.Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.